Billionaire investor Carl Icahn wants all 11 seats on the board of consumer products maker Clorox Co (CLX.N), which has twice rejected his offers this summer to purchase the company. In a letter to Clorox on Friday, Icahn said he wants to nominate himself, his son and nine other people for election to Clorox' board at its next annual shareholder meeting. The notice came just a day after Forest Laboratories Inc (FRX.N) won its showdown with Icahn, as its shareholders backed that company's slate of 10 board members over nominees Icahn had proposed. Icahn, Clorox's largest shareholder, was twice rebuffed by the bleach maker in July. His most recent offer was to buy the company for $80 per share, which Clorox on July 26 called "inadequate."
The Clorox Company (Clorox) is a manufacturer and marketer of consumer and institutional products. Shares of CLX traded higher by 1.06% or $0.68/share to $64.80. In the past year, the shares have traded as low as $60.56 and as high as $75.44. On average, 1861400 shares of CLX exchange hands on a given day and today's volume is recorded at 440182.
Forest Laboratories, Inc. (Forest) develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. Shares of FRX fell by 0.75% or $-0.25/share to $32.93. In the past year, the shares have traded as low as $27.27 and as high as $40.52. On average, 3858540 shares of FRX exchange hands on a given day and today's volume is recorded at 324288.
Source
